Healthcare Industry News: angina
News Release - October 12, 2006
Vasomedical Introduces Wireless Data Management System
Electronic Communication Module uses Bluetooth(R) TechnologyWESTBURY, N.Y.--(HSMN NewsFeed)--Vasomedical, Inc. (OTCBB: VASO.OB ), a leader in noninvasive, outpatient management of cardiovascular diseases, today introduced its Electronic Communication Module (ECM) for the Lumenair(TM) EECP® Therapy System. The ECM utilizes industry-leading Bluetooth® technology to wirelessly transfer encrypted patient and treatment data to a dedicated computer. Users are then able to easily access, view, print and archive patients' data with the included laptop or desktop computer and printer. The ECM is designed to be integrated with an electronic medical record software system.
"The ECM is an exciting product enhancement to our clinically-proven, premier EECP® therapy system, the Lumenair(TM). We are driven by the patients' need for optimal clinical outcomes and by our customers' need for efficient and practical technical solutions. The ECM enables clinicians to electronically transfer treatment data for use in patient care and reimbursement documentation, all with minimal time requirements. We are proud to combine this cutting-edge information technology with our proprietary, state-of-the-art EECP® product technology," commented Thomas Glover, president and chief executive officer of Vasomedical, Inc.
About the Lumenair(TM) EECP® Therapy System
The Lumenair(TM) EECP® Therapy System is the latest of Vasomedical's products for the treatment of patients with ischemic heart disease. Its design enhances patient comfort and monitoring while optimizing treatment parameters, all with improved ease-of-use and reduced space requirements.
About Vasomedical, Inc. and EECP® Therapy
Vasomedical, Inc. develops, manufactures and markets EECP® therapy systems to deliver its proprietary form of enhanced external counterpulsation therapy. EECP® therapy is a noninvasive, outpatient therapy used in the treatment of ischemic cardiovascular diseases, currently used to manage chronic stable angina and heart failure. The therapy increases blood flow and oxygen supply to the heart muscle and other organs and decreases the heart's workload and need for oxygen, while also improving function of the endothelium, the inner lining of blood vessels throughout the body, lessening resistance to blood flow. These actions reduce or eliminate symptoms of angina and heart failure, and improve the quality of life for thousands of people worldwide. For more information visit www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipated", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the risk factors reported from time to time in the Company's SEC reports, including the ability of the Company to continue as a going concern. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Source: Vasomedical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
